Omnium Risk

Omnium Risk uses dynamic and predictive modelling to deliver critical data and insights on product risk, so you can predict the likelihood of success for Phase I assets 4 times more accurately than existing risk models. Additionally, it allows you to project R&D costs and time to market in more detail than ever before.

Identifies which in-house and competitor drugs are most likely to reach the market. Proprietary algorithms, powered by machine learning, enable comparisons across products and indications to better balance portfolio risk:

• Product Specific Probability of Technical and Regulatory Success (PTRS)
• Fully transparent risk audits
• Success rate benchmarks

Predicts when key development milestones will occur, enabling comparison of progress against competitors and highlighting products with first-in-class potential:

• Time-in-phase predictions
• Launch date predictions
• Market entry order predictions

Provides the industry’s first comprehensive clinical trial costing model, applying real-world data to over 50,000 trials, which allows for a better assessment of likely costs across the development cycle:

• Overall product development cost across all phases
• Clinical trial cost predictions
• Industry benchmarks by indication

Focused on the indication-specific endpoints most likely to lead to regulatory approval. Updated daily, it aggregates and standardises trial outcomes for indications and products.

Tracks and integrates clinical trials from three key industry sources alongside key commercial insights, so you can fully understand company development plans and pipelines.

Identifies and tracks critical product lifecycle and company events, such as trial initiations, regulatory decisions and financial results, so key market catalysts or competitor activities can be efficiently monitored.